Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review 2024: Drug Code/INN, Patent/Expiry, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
October 24, 2024 09:59 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides...
Samsung Bioepis Presents Totality-of-the-Evidence Supporting Extrapolation of EPYSQLI™ (SB12; Eculizumab)’s Indication, at the European Society of Paediatric Nephrology (ESPN) 2024
September 23, 2024 02:00 ET
|
Samsung Bioepis
Samsung Bioepis Presents Totality-of-the-Evidence Supporting Extrapolation of EPYSQLI™ (SB12; Eculizumab)’s Indication, at the European Society of Paediatr
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congress 2024
June 14, 2024 03:00 ET
|
Samsung Bioepis
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congre
Atypical Hemolytic Uremic Syndrome (aHUS) Market and Forecast Through 2032 Reveals Growth and Treatment Shifts
April 08, 2024 04:04 ET
|
Research and Markets
Dublin, April 08, 2024 (GLOBE NEWSWIRE) -- The "Atypical Hemolytic Uremic Syndrome (aHUS) - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ...
Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review 2024
February 23, 2024 07:31 ET
|
Research and Markets
Dublin, Feb. 23, 2024 (GLOBE NEWSWIRE) -- The "Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides...